Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyMolina Healthcare Respiratory Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy 103

    Respiratory Pathogen Panel Testing Policy

    Customize your policy alerts

    Sign up for Molina Healthcare Policy 103 alerts

    Get alerted when Policy 103 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Reimbursement, billing, coding, and medical-necessity requirements for outpatient respiratory pathogen panel testing for Passport by Molina Healthcare members in Kentucky.

    Policy Summary
    PayerMolina Healthcare
    PolicyRespiratory Pathogen Panel Testing Policy
    Policy CodePolicy 103
    Change TypeNew policy
    Effective DateNov 9, 2026
    Last ReviewNov 9, 2026
    Next Review DateN/A
    Key ActionSubmit respiratory pathogen panel testing as a single billable service with one unit of service per test and document medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Units per test
    ≤5Generally appropriate panel size

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >5Expanded panel threshold
    3Required medical-necessity criteria
    6Covered CPT codes
    9Nonreimbursable CPT/PLA codes

    Medical Necessity and Coverage Requirements

    Core medical-necessity criteria

    All of the following criteria must be met for respiratory pathogen panel testing to be medically reasonable and necessary:

    ALL of the following

    • The panel reports 5 or fewer respiratory pathogens.≤5 respiratory pathogens
    • Testing is performed for an individual who is at high risk for complications from respiratory viral infections.
    • Test results will be used to guide or alter treatment management.

    Expanded panel exceptions

    Panels with more than five targets are generally not medically necessary in routine outpatient settings, but may be considered when clinically justified by one or more of the following circumstances:

    ONE or more of

    • Severity of illness supports expanded testing.
    • The patient is immunocompromised.
    • The patient has increased risk for complications.
    • Care is delivered in an emergency department, observation, or inpatient setting.

    Noncovered and denial-risk circumstances

    Testing may not be reimbursable or may be denied in the following circumstances:

    ONE or more of

    • Routine screening or broad population testing is performed without a covered clinical indication, unless otherwise required by applicable program guidance.
    • Component assays for the same organism targets are billed separately from a multiplex panel without documentation supporting distinct testing methodologies, separate clinical necessity, or repeat testing due to a clinical change in condition.
    • Duplicate or overlapping respiratory testing is billed.
    • Diagnosis codes do not support medical necessity.
    • Testing is performed outside covered benefit guidelines.

    Covered Codes and Billing Parameters

    Covered respiratory pathogen CPT codesCPTCovered
    87428A combined (multiplex) antigen immunoassay test performed on a patient specimen to detect SARS-CoV-2, Influenza virus type A and Influenza virus type B.
    87631A multiplex nucleic acid amplification test (NAAT/PCR) performed on a respiratory specimen to detect multiple respiratory viruses (3-5 targets) in a single assay.
    87636A multiplex molecular (NAAT/PCR) laboratory test that simultaneously detects and differentiates three respiratory viruses from a single patient specimen: SARS-CoV-2, Influenza virus type A and Influenza virus type B.
    87637A multiplex molecular (NAAT/PCR) laboratory test that simultaneously detects and differentiates four respiratory viruses from a single patient specimen: SARS-CoV-2, Influenza virus type A, Influenza virus type B and Respiratory syncytial virus (RSV).
    87812A rapid antigen combination test that detects COVID-19 and influenza A & B at the same time, with results read by direct visual (optical) observation rather than by an instrument.
    87913Genotype (mutation) analysis of SARS-CoV-2 (COVID-19) using nucleic acid (DNA or RNA) testing.
    Not reimbursable respiratory pathogen CPT and PLA codes — denied unless an applicable exception is metCPTNot Covered
    0115UA pathogen panel that detects 18 viral and 2 bacterial respiratory pathogens from a nasopharyngeal specimen.
    0202UProprietary Laboratory Analysis (PLA) for detecting respiratory pathogens. This test can detect 22 different respiratory pathogens including SARS-CoV-2, qualitative RT-PCR, and nasopharyngeal swab. Each pathogen reported as detected or not detected.
    0223UProprietary Laboratory Analysis (PLA) for detecting respiratory pathogens. This test can detect 22 different respiratory pathogens including SARS-CoV-2, qualitative RT-PCR, and nasopharyngeal swab. Each pathogen reported as detected or not detected.
    0225UProprietary Laboratory Analysis (PLA) for detecting multiple viral and bacterial respiratory pathogens, including SARS-CoV-2.
    0528UProprietary Laboratory Analysis (PLA) code that describes a multiplex molecular diagnostic test for lower respiratory tract infections.
    0563UProprietary Laboratory Analysis (PLA) code that describes a multiplex molecular test for respiratory and sore-throat infections.
    0564UProprietary Laboratory Analysis (PLA) code used to report a multiplex molecular test for sore-throat-associated respiratory infections.
    87632The detection of respiratory viruses using nucleic acid amplification for 6 to 11 targets.
    87633The detection of respiratory viruses using nucleic acid amplification for 12 to 25 targets.
    ICD-10-CM diagnosis codes and LCD requirementsICD-10
    No codes listed
    Units of Service
    Allowed units1 unit of service (UOS) per test
    Billing treatmentRespiratory pathogen panel testing is treated as a single billable service
    Applicable settingOutpatient respiratory pathogen panel testing
    Generally Appropriate Outpatient Panel Size
    Generally appropriate panel sizeNo more than five respiratory targets
    Outpatient usePanels with no more than five respiratory targets are generally appropriate in outpatient settings

    Billing, Documentation, and Denial Prevention

    Billing Rule

    Meet Medical-Necessity and Billing Requirements

    Submit respiratory pathogen panel testing as a single billable service with one unit of service (UOS) per test. Testing must be medically necessary, clinically appropriate, and billed in accordance with applicable CMS requirements, CPT coding guidance, NCCI principles, and applicable Medicare LCDs and billing articles.

    • Respiratory pathogen panel testing is reimbursable when performed in medically appropriate outpatient settings, including physician offices, outpatient hospital facilities, emergency departments, urgent care centers, and independent clinical laboratories.
    • Professional charges: submit on CMS-1500 or electronic equivalent.
    • Facility charges: submit on UB-04 or electronic equivalent.
    Denial Risk

    Key Terms

    CMS
    Full nameCenters for Medicare & Medicaid Services
    Medicare responsibilityA federal agency within the United States Department of Health and Human Services that administers the Medicare program
    State partnershipWorks with state governments to administer Medicaid, the Children’s Health Insurance Program (CHIP), and health insurance portability standards
    Multiplex Reverse-Transcription Polymerase Chain Reaction (RT-PCR)
    TechniqueA molecular technique
    ProcessSimultaneously amplifies and detects multiple target RNA sequences
    Application
    Policy Summary
    PayerMolina Healthcare
    PolicyRespiratory Pathogen Panel Testing Policy
    Policy CodePolicy 103
    Change TypeNew policy
    Effective DateNov 9, 2026
    Last ReviewNov 9, 2026
    Next Review DateN/A
    Key ActionSubmit respiratory pathogen panel testing as a single billable service with one unit of service per test and document medical necessity.
    SourceLink
    On This Page
    Medical Necessity and Coverage RequirementsCovered Codes and Billing ParametersBilling, Documentation, and Denial PreventionKey Terms
    Billing is inconsistent with CMS/NCCI coding standards.
    Medical-necessity requirementTesting must also be for an individual at high risk for complications, with results used to guide or alter treatment management
    Expanded Panel Size
    Expanded panel sizeMore than five respiratory targets
    Routine outpatient statusGenerally not considered medically necessary in routine outpatient settings
    Potential considerationMay be considered when clinically justified by severity of illness, immunocompromised status, increased risk for complications, or care in an emergency department, observation, or inpatient setting

    Avoid Screening and Duplicative Testing

    Do not bill routine screening or broad population testing without a clinical indication unless otherwise required by applicable program guidance. Avoid duplicate or overlapping respiratory testing unless an applicable clinical exception supports the service.

    • Testing should evaluate, diagnose, or manage a suspected respiratory infection.
    • Noncovered screening or duplicative testing may be denied.
    Billing Rule

    Prevent Unbundling of Panel Components

    Do not separately bill component respiratory viral assays for organism targets detected by a multiplex panel. Separate billing is not reimbursable unless documentation supports a recognized exception.

    • Distinct testing methodologies
    • Separate clinical necessity
    • Repeat testing due to a clinical change in condition
    Documentation Required

    Document Required Medical-Necessity Criteria

    Document all medical-necessity criteria supporting the panel. The record must establish that the panel reports five or fewer respiratory pathogens, the patient is at high risk for complications from respiratory viral infections, and the results will be used to guide or alter treatment management.

    • Document the panel size and the respiratory targets reported.
    • Document high-risk status, such as immunocompromised status or another increased risk for complications.
    • Document the suspected respiratory infection and the clinical circumstances supporting testing.
    • Document how test results will guide or alter treatment management.
    Documentation Required

    Justify Expanded Panels

    Panels detecting more than five respiratory targets are generally not medically necessary in routine outpatient settings. If an expanded panel is performed, document the specific clinical justification and setting supporting its use.

    • Severity of illness
    • Immunocompromised status
    • Increased risk for complications
    • Care delivered in an emergency department, observation, or inpatient setting
    Billing Rule

    Use the Applicable Claim Form

    Use the claim form that corresponds to the billing entity and charge type, while reporting the respiratory pathogen panel as one billable service with one unit of service.

    • Professional charges: CMS-1500 or electronic equivalent.
    • Facility charges: UB-04 or electronic equivalent.
    Denial Risk

    Manage Denial and Recovery Risk

    Support every claim with diagnosis coding, documentation, and billing that comply with the policy and applicable coding standards. Unsupported medical necessity, noncovered screening, duplicate testing, improper coding, or services outside covered benefit guidelines may result in denial, adjustment, recoupment, or recovery of payment.

    • Claims may be reviewed for compliance with Passport by Molina Healthcare reimbursement policy and applicable program requirements.
    • Overpayments may be recovered through offsets or refund requests as permitted by law, regulation, and contract terms.
    • Providers may dispute adjustments or denials through the applicable appeal process.
    • Codes are for reference only, may not be all-inclusive, and do not guarantee coverage; use current industry-standard coding practices and verify benefit coverage.
    Used for multiplex respiratory pathogen testing
    Unit of Service (UOS)
    DefinitionA standardized measure used to quantify the delivery of healthcare services
    ScopeCan include various modalities and elements
    Governing requirementsDefined by state and federal regulations